Hepatocellular carcinoma (HCC) is the most prevalent type of liver cancer and the third
leading cause of cancer deaths worldwide. Current therapies for advanced HCC, including …

Hepatocellular Carcinoma (HCC) is the most prevalent type of liver cancer and the third
leading cause of cancer deaths worldwide. Drugs approved for first-and second-line therapy …

Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality
worldwide. Here we described a genome-wide screen by CRISPR activation (CRISPRa) …

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide.
Sorafenib is the only first‐line pharmaceutical approved for the treatment of HCC, and has …

Existing drug therapies for hepatocellular carcinoma (HCC), including sorafenib, extend
patient survival by only three months. We sought to identify novel druggable targets for use …

Clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR‐associated 9
activation (CRISPRa) systems have enabled genetic screens in cultured cell lines to …

Background & Aims It has been a challenge to identify liver tumor suppressors or oncogenes
due to the genetic heterogeneity of these tumors. We performed a genome-wide screen to …

Hepatocellular carcinoma (HCC) is a devastating and prevalent cancer with limited
treatment options. Technological advances have enabled genetic screens to be employed in …

Background Epigenetic silencing of tumor suppressor genes (TSGs) is a key feature of
oncogenesis in hepatocellular carcinoma (HCC). Liver-targeted delivery of CRISPR …

Cancer genomics consortia have charted the landscapes of numerous human cancers.
Whereas some mutations were found in classical oncogenes and tumor suppressors, others …